## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($91.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T110841 | Somewhat-Bullish | Relevance: 100%
- Revvity, Inc. launched Signals Xynthetica, an AI Models-as-a-Service, to integrate AI into lab workflows for molecular and materials design, aiming to enhance its software revenue growth story. This platform is critical for Revvity's long-term strategy to build a high-quality, software-heavy earnings base, despite ongoing pressures in its legacy diagnostics business. The move reinforces Revvity's investment narrative focused on high-margin software capabilities.

**2. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T112310 | Bullish | Relevance: 100%
- Revvity, Inc. launched Signals Xynthetica, an AI-powered platform for molecular and materials design, aiming to integrate AI directly into laboratory workflows. This move reinforces Revvity's strategy to shift towards higher-margin, software-enabled tools, offsetting pressures in legacy diagnostics and supporting recurring digital revenue. Despite the promising AI advancements, the company still faces risks from tightening reimbursement policies and pricing pressure in diagnostics, with its long-term financial health depending on a balance between AI investments and capital returns.

**3. Revvity introduces AI-augmented design platform for molecular and materials discovery**
- Source: BioSpectrum India | 20251222T074102 | Bullish | Relevance: 100%
- Revvity, Inc. has announced Signals Xynthetica™, an AI-augmented design platform for molecular and materials discovery. This platform integrates in-silico generation, predictive modeling, and experimental validation, allowing scientific teams to iteratively refine candidate molecules. Signals Xynthetica aims to bridge the gap between powerful AI models and real-world experimental data, providing a Models-as-a-Service (MaaS) offering to streamline the application and governance of predictive models in scientific research.

**4. Raymond James reiterates Outperform rating on Revvity stock after site visit**
- Source: Investing.com | 20251220T020857 | Bullish | Relevance: 100%
- Raymond James has reiterated an Outperform rating and a $115.00 price target on Revvity Inc (NYSE:RVTY) after visiting the company's non-BioLegend reagent manufacturing facility. Despite near-term challenges like foreign exchange movements, the firm expressed reinforced comfort with Revvity's long-term fundamentals, highlighting the under-discussed non-BioLegend reagents business now nearing $300 million. The company, with a market cap of $10.91 billion and $2.81 billion in revenue, also reported recent strategic moves including an acquisition and plans for an AI Models-as-a-Service offering, despite some analyst downgrades citing limited upside potential.

**5. Goldman Sachs and KeyBanc are Bullish on Danaher (DHR)**
- Source: Finviz | 20251221T210821 | Neutral | Relevance: 55%
- Goldman Sachs initiated coverage on Danaher Corporation (NYSE: DHR) with a Buy rating and a $265 price target, citing its strong bioprocessing franchise and expectations for easing equipment market overhangs. KeyBanc Capital Markets also highlighted Danaher as a top pick for 2026 in the Life Sciences Tools & Services industry, anticipating recovery and conservative core revenue growth guidance. Both firms foresee increased biopharma spending and a positive outlook for Danaher, a leading global life sciences and diagnostics innovation company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Elevated short interest (9.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.4x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.3B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.4 |
| Current P/E | 19.9 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.2% to -1.9% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.86), momentum weakening. RSI neutral at 49. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.87% (CS: 21) | Neutral |
| RSI_14 | 48.7 | Neutral |
| MACD Histogram | -0.86 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.030x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.74
- **Stop Loss:** $91.66 (6.2% risk)
- **Target:** $103.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 197
- **Position Value:** $19,254.78
- **Portfolio %:** 19.25%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*